Gadolinium(III)-based Polymeric Magnetic Resonance Imaging Agents for Tumor Imaging

Area of Science:

• Medical Imaging
• Materials Science
• Nanotechnology

Background:

• Magnetic resonance imaging (MRI) relies on contrast agents (CAs) to enhance signal-to-noise ratio.
• Current clinical MRI CAs are typically low molecular weight gadolinium(III) (Gd(III)) chelates.
• Gd(III)-based polymeric MRI agents (mCAs) offer advantages like high relaxivity and prolonged circulation time.

Purpose of the Study:

• To review recent progress in the design, properties, and applications of Gd(III)-based macromolecular contrast agents (mCAs).
• To highlight emerging trends in smart-responsive and multifunctional mCAs for advanced MRI applications.
• To discuss the potential of mCAs in tumor microenvironment-stimulated MRI, multi-mode imaging, and theranostics.

Main Methods:

• Literature review focusing on recent advancements in mCA research.
• Analysis of various mCA structures and their impact on MRI performance.
• Evaluation of in vitro and in vivo studies on mCA efficacy and applications.

Main Results:

• Gd(III)-based mCAs demonstrate superior relaxivity and blood circulation times compared to small-molecule CAs.
• Diverse mCA structures have been developed, leading to enhanced MRI capabilities.
• Emerging mCAs exhibit smart responsiveness and multi-functional properties, expanding their diagnostic and therapeutic potential.

Conclusions:

• Macromolecular contrast agents represent a significant advancement in MRI technology.
• Continued research into mCA design promises improved diagnostic accuracy and novel theranostic applications.
• Smart and multifunctional mCAs are poised to revolutionize future MRI examinations.